Pilot Acute Safety Evaluation of Innocell™ Cancer Immunotherapy in Canine Subjects

Abstract EN

Background.

We are developing cancer immunotherapy based on the use of autologous tumor tissue that has been rendered replication-incompetent but maintains phenotype and metabolic activity post-preparation.

Aim.

The aim of this study was to evaluate safety and tolerance to injection of the inactivated tumor cell and adjuvant preparation (Innocell™) within 24 hours of administration in a pilot study in canine patients with solid organ tumors.

Methodology.

Three canine patients demonstrating accessible solid organ tumors of various types were assessed in this study.

The local site injection was monitored post-treatment.

Clinical signs of adverse reactions were monitored for 24 hours post-treatment.

Blood samples were taken pre-treatment and at 8 and 24 hours post-treatment for all subjects.

One subject provided samples at 7 days post-treatment.

All blood samples were analyzed for cytokine content for both immune system-associated and tumor-associated cytokines.

Results.

No signs of adverse reactions at the site of injection or systemically were observed in the study period.

A slight fever and lethargy were reported in one subject by the owner post-vaccination.

Immune system-associated cytokine levels in two of the three animals were elevated post-treatment.

Tumor-associated cytokine levels in all three subjects declined post-treatment from baseline levels with the effect most prominent in the subject with a non-excised tumor.

Conclusion.

Subcutaneous injection of the inactivated tumor cells and adjuvant was well tolerated in this pilot study.

Cytokine responses observed were in line with the intended use of the treatment in stimulating immune response without adverse clinical observations.

Additional evaluation is warranted.